Hybrigenics has started dosing the first patients in France and the US in a double-blind, placebo-controlled Phase II study in elderly or frail acute myeloid leukaemia (AML) patients. Data are expected in Q418 or H119. Additionally, an open-label Phase II study in patients with chronic myeloid leukaemia (CML) in combination with imatinib continues; an update will be provided by Q117. Hybrigenics has an R&D collaboration with Servier focused on oncology, from which it received a €1.5m
06 Dec 2016
First patients enrolled in AML Phase II trial
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
First patients enrolled in AML Phase II trial
Hybrigenics SA Class A (ALHYG:PAR) | 0 0 0.0% | Mkt Cap: 25.2m
- Published:
06 Dec 2016 -
Author:
Juan Pedro Serrate -
Pages:
5
Hybrigenics has started dosing the first patients in France and the US in a double-blind, placebo-controlled Phase II study in elderly or frail acute myeloid leukaemia (AML) patients. Data are expected in Q418 or H119. Additionally, an open-label Phase II study in patients with chronic myeloid leukaemia (CML) in combination with imatinib continues; an update will be provided by Q117. Hybrigenics has an R&D collaboration with Servier focused on oncology, from which it received a €1.5m